CCJ March 13th Options Begin Trading

Cameco (CCJ) is being presented as an options trade idea: selling a $129 put (bid $7.05) would commit purchase at $129 with an effective cost basis of $121.95 given the $129.91 stock price, a 58% probability to expire worthless and a 5.47% return (46.43% annualized) if it does. Conversely, selling a $136 covered call (bid $8.40) against shares bought at $129.91 would cap upside at $136 for an 11.15% total return if called at the March 13 expiration, with a 52% chance to expire worthless and a 6.47% premium boost (54.94% annualized). Implied volatilities are 56% on the put and 64% on the call versus a trailing 12-month volatility of 50%, and the publisher will track changing odds and contract histories on its site.

Analysis

Market structure: Option sellers and yield-focused equity holders are the clear near-term winners — the $129 put (bid $7.05) and $136 call (bid $8.40) offer 5.47% and 6.47% single-expiry boosts (46% and 55% annualized) into the Mar 13 expiry (~6 weeks). Buyers of upside (> $136) are the latent winners if uranium catalysts materialize; holders are hurt by being called away or assigned into commodity/cash exposure. The 56%/64% implied vols vs 50% realized vol show meaningful skew and risk premium which inflates option income for sellers.

Risk assessment: Tail risks include regulatory shifts (reactor licensing or mine suspensions), geopolitical supply shocks (Kazakhstan/Russia disruptions), or a sudden collapse in uranium spot (-30%+) — any of which could send CCJ below $100 quickly and force assignment/margin strain. Immediate window (days–6 weeks) is dominated by theta/IV moves and catalysts; short-term (3–6 months) by Q1 production/contract announcements; long-term (1–3 years) by global reactor builds and utility contract rollouts. Hidden risks: assignment liquidity, tax treatment of options, and correlation spikes with uranium spot that can blow up naked sellers.

Trade implications: If willing to own CCJ at ~$122, sell cash‑secured Mar13 $129 puts size-limited to 1–2% portfolio (effective basis $121.95); close or hedge if CCJ < $110 or IV rises >10 pts. If already long CCJ, sell Mar13 $136 covered calls on 25–50% of shares to lock 11.15% gross to expiry and roll if price >$136 with >3% momentum. For volatility plays, consider a short‑dated put credit spread (sell $129/buy $120) to cap downside or a calendar debit on calls to buy time if expecting a later uranium catalyst.

Contrarian angles: The market is pricing elevated short-term event risk (IV skew) despite realized volatility lagging — options sellers are being well compensated but underestimate tail correlation with spot uranium. The trade is underdone if you expect a government strategic purchase or reactor restart; conversely overdone if demand disappoints and spot drops >15%. Historical parallels: 2020 uranium squeezes show rapid re-rating on government buys, but also sudden unwinds; therefore size positions small, define hurt thresholds, and prefer defined-risk structures.

Key Decisions for Investors

• Sell cash‑secured Mar13 2026 CCJ $129 puts (bid ~7.05) sized to 1–2% of portfolio (one contract per 100 shares ≈ $12.2k notional); effective buy price $121.95. Close or convert to long if CCJ < $110, or hedge if implied vol rises >10 percentage points.
• If long CCJ, sell Mar13 2026 $136 covered calls on 25–50% of holdings (collect ~$8.40) to realize ~11.15% to expiry; plan to roll up-and-out if share price >$140 with >3% daily momentum or buy back if assigned undesirably before a major catalyst.
• Deploy defined‑risk bearish hedge: buy Mar13 2026 $110 puts and sell Mar13 $2026 $100 puts (net debit) sized to cover downside for existing CCJ exposure; use this if CCJ trades below $120 to limit tail losses.
• Implement a relative-value pair: small long CCJ vs short URA (Global X Uranium ETF) sized 0.5–1% portfolio to capture stock-specific re-rating if CCJ wins contracts; unwind if divergence >10% absolute within 60 days.
• Set specific monitoring triggers: alert on uranium spot moves ±10%, Kazatomprom/Novatek announcements, US/Canadian strategic purchases, or CCJ guidance changes — act within 48 hours of any trigger to either tighten stops or increase allocation.